Healthcare Industry News: drug-eluting stent
News Release - January 15, 2009
Court of Appeals Overturns 2005 Patent Verdict Against CordisWARREN, N.J., Jan. 15 -- (Healthcare Sales & Marketing Network) -- The Court of Appeals for the Federal Circuit in Washington, D.C. today found Boston Scientific Corporation's Ding patent invalid, and reversed a 2005 jury finding that Cordis Corporation's CYPHER® Sirolimus-eluting Coronary Stent infringed that patent.
Cordis is very pleased with this significant Court decision.
The original jury verdict was rendered in July 2005 in Wilmington, Delaware. The Ding patent had claimed a two-layer drug coating for a drug-eluting stent, which the Appeals Court found to be obvious in light of earlier issued patents.
About Cordis Corporation
Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with interventional cardiologists worldwide to treat millions of patients who suffer from vascular disease.
More information about Cordis Corporation can be found at www.cordis.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.